Substitu	te for form 1449B/PTO				Complete if Known
				Application Number	10/533,844
INF	DRMATION DIS	SCLOS	SURE	Filing Date	May 4, 2005
STA	STATEMENT BY APPLICANT			First Named Inventor	Hagen, Frederick S.
				Art Unit	1649
	(Use as many sheets as	necessary)		Examiner Name	Olgo N. Chemychou Stephen Gucker
Sheet	1	of	5	Attorney Docket Number	017881-001010US

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number Kind Code ^{2 (Finese)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA	US-5,604,102	02-18-1997	McConlogue et al.			
	AB	US-5,658,754	08-19-1997	Kawasaki			
	AC	US-6,153,380	11-28-2000	Nolan et al.			
	AD	US-6,175,057	01-16-2001	Mucke et al.			
	AE	US-6,267,962	07-31-2001	Hart et al.			
	AF	US-6,365,634	04-02-2002	Russell et al.			
	AG	US-6,420,110	07-16-2002	Gyuris et al.			
	AH	US-6,440,698	08-27-2002	Gumey et al.			
	Al	US-2002/0127564	09-12-2002	Nolan			
	AJ	US-2006/0275833	12-07-2006	Hagen			

	FOREIGN PATENT DOCUMENTS									
	Cite	Fore	Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.1	Country Code ³	Number ⁴	Kind Code ⁶	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶		
	AK	PCT	WO 98/21589	A1	05-22-1998	University of Pennsylvania				
	AL	PCT	WO 98/39483	A1	09-11-1998	Ventana Genetics, Inc.				
	АМ	PCT	WO 99/24617	A1	05-20-1999	Ventana Genetics, Inc.				
	AN	PCT	WO 01/49097	A2	07-12-2001	Bienkowski et al.				
	AO	PCT	WO 03/57165	A2	07-17-2003	The Rockefeller University				
	AP	PCT	WO 04/18997	A2	03-04-2004	Neurogenetics, Inc.				
	AQ	PCT	WO 04/42074	A2	05-21-2004	Icogen Corp.				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

Examiner Signature		Date Considered	
	· · · · · · · · · · · · · · · · · · ·		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with ext communication to applicant.

"Applicant's uneque citation designation number (optional), "Applicant's lost place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO					Complete if Known
				Application Number	10/533,844
INFO	RMATION DIS	CLOS	SURE	Filing Date	May 4, 2005
STATEMENT BY APPLICANT			CANT	First Named Inventor	Hagen, Frederick S.
				Art Unit	1649
(Use as many sheets as necessary)				Examiner Name	Olga N. Chemyshev Stephen Gac
Sheet	2	of	5	Attorney Docket Number	017881-001010US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-sissue number(s), publisher, city and/or country where published,	T²
	AR	BROWN, * Metal-recognition by repeating polypeptides," Nat. Biotechnol. 15:269-272 (1997).	
	AS	CEDAZO-MINGUEZ et al., "Nicergoline stimulates protein kinase C mediated α-secretase processing of the amyloid precursor protein in cultured human neuroblastoma SH-SYSY cells," Neurochem. Int. 35:307-315 (1999).	
	AT	CULL et al., "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor," Proc. Natl. Acad. Sci. USA 89:1865-1869 (1992).	
	AU	DE STROOPER et al., "Exchanging the extracellular domain of amyloid precursor protein for horseradish peroxidase does not interfere with α-secretase cleavage of the β-amyloid region, but randomizes secretion in Madin-Darby canine kidney cells," J. Biol. Chem. 270:30310- 30314 (1995).	
	AV	FIELDS and SONG, "A novel genetic system to detect protein-protein interactions," <i>Nature</i> 340:245-246 (1989).	
	AW	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amylold precursor protein," Nature 373:523-527 (1995).	
	AX	GILCHRIST et al., "Use of peptides-on-plasmids combinatorial library to identify high-affinity peptides that bind rhodopsin," Methods Enzymol. 315:388-404 (2000).	
	AY	GOTZ et al., "Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils," Science 293:1491-1495 (2001).	
	AZ	HARTLEY et al., "Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons," J. Neurosci. 19:8876-8884 (1999).	
	ВА	HSIAO et al., "Correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice," Science 274:99-102 (1996).	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /SG/

Examiner Signature	Date Considered	
-----------------------	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicants unique citation designation number optionally. **Applicants* is to base a check mark here if English language Translation is attached.

Substitute	for form 1449B/PTO				Complete if Known	
				Application Number	10/533,844	
INFO	RMATION DIS	CLOS	SURE	Filing Date	May 4, 2005	
STA	STATEMENT BY APPLICANT			First Named Inventor	Hagen, Frederick S.	
				Art Unit	1649	
	(Use as many sheets as necessary)			Examiner Name	Olga N. Ohemyshev Stephen Gu	cker
Sheet	3	of	5	Attorney Docket Number	017881-001010US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, sympostum, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	ВВ	KANG et al., "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell- surface receptor," Nature 325:733-736 (1987).	
	вс	KAWARABAYASHI et al., "Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease," J. Neurosci. 21:372-381 (2001).	
	BD	KINSELLA et al. "Retrovirally delivered random cyclic peptide libraries yield inhibitors of interleukin-4 signaling in human B cells," J. Biol. Chem. 277:37512-37518 (2002).	
	BE	KJAERGAARD ef al., "Novel Zn ² "-chelating peptides selected from a fimbria-displayed random peptide library," <i>Appl. Environ. Microbiol.</i> 67:5467-5473 (2001).	
	BF	LABEAN and KAUFFMAN, "Design of synthetic gene libraries encoding random sequence proteins with desired ensemble characteristics," <i>Protein Sci.</i> 2:1249-1254 (1993).	
	BG	LAMMICH et al., "Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease," Proc. Natl. Acad. Sci. USA 96:3922-3927 (1999).	
	ВН	LOPEZ-PEREZ et al., "Proprotein convertase activity contributes to the processing of the Alzheimer's β-amyloid precursor protein in human cells: evidence for a role of the prohomone convertase PC7 in the constitutive α-secretase pathway," J. Neurochem. 73:2056-2062 (1999).	
	ВІ	LU et al., "Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions," Biotechnology 13:386-372 (1995).	
	BJ	MAZUR-KOLECKA et al., "Accumulation of Alzheimer amyloid-peptide in cultured myocytes is enhanced by serum and reduced by cerebrospinal fluid," J. Neuropathol. Exp. Neurol. 56(3):263-272, Abstract only, (1997).	
	вк	MILLER et al., "Use of retroviral vectors for gene transfer and expression," Methods Enzymol. 217:581-599 (1993).	
	BL	MULLAN et al., "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β -amyloid," Nat. Genet. 1:345-347 (1992).	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 809. Draw line through obtation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicants unique clatifor designation number (optional)**, "Applicants into its place a check mark here if English language Translation is attached.

Substitute f	for form 1449B/PTO				Complete if Known
				Application Number	10/533,844
INFO	RMATION DIS	CLOS	SURE	Filing Date	May 4, 2005
STAT	STATEMENT BY APPLICANT			First Named Inventor	Hagen, Frederick S.
				Art Unit	1649
	(Use as many sheets as necessary)			Examiner Name	Olga N. Cherrysher Stephen Gacke
Sheet	4	of	5	Attorney Docket Number	017881-001010US

		NON PATENT LITERATURE DOCUMENTS				
	_	HONT ATENT ETERATORE DOCUMENTO	_			
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	вм	MURTHY, "Characterization of the interleukin 3 receptor," Exp. Hematol. 18(1):11-17 (1990).				
	BN	NILSBERTH et al., "The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation," Nat. Neurosci. 4:887-893 (2001).				
	BO NILSSON et al., "α-1-antichymotrypsin promotes β-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease," J. Neurosci. 21:1444-1451 (2001).					
	BP NORMAN et al., "Genetic selection of peptide inhibitors of biological pathways," Science 285:591-595 (1999).					
	BQ	PARVATHY et al. "Alzheimer's amyloid precursor protein α-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase, "Biochemistry 37:1680-1685 (1998).				
	BR	PONCET, "CD24, a glycosylphosphatidylinositol-anchored molecules is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors," <i>Acta. Neuropathol.</i> 91(4):400–408, Abstract only, (1996).				
	BS	RIAN et al., "A signal sequence trap based on cell enrichment using anti-CD19 antibody coated magnetic beads," Scand. J. Immunol. 54:280-284 (2001).				
	вт	SCOTT and SMITH, "Searching for peptide ligands with an epitope library," Science 249:386-390 (1990).				
	BU	SELKOE, "Alzheimer's disease: genes, proteins, and therapy," <i>Physiol. Rev.</i> 81:741-766 (2001).				
	вv	SELKOE, "Alzheimer's disease is a synaptic failure," Science 298:789-791 (2002).				
	BW	V SINHA, et al., "Purification and cloning of amyloid precursor protein β-secretase from human brain," Nature 402:537-540 (1999).				
	BX SISODIA, "β-amyloid precursor protein cleavage by a membrane-bound protease," Proc. Natl. Acad. Sci. USA 89:6075-6079 (1992).					
xaminer		Date Considered				

Signature		Considered	- 1

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant: unique clatton designation number (polition) *Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/533,844
INFORMATION DISCLOSURE				Filing Date	May 4, 2005
STATEMENT BY APPLICANT			CANT	First Named Inventor	Hagen, Frederick S.
				Art Unit	1649
	(Use as many sheets as necessary)			Examiner Name	Olga N. Chomyshov Stephen Gucke
Sheet	5	of	5	Attorney Docket Number	

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *			T²		
	BY	STEINER and HAASS, "Intramembrane proteotysis by presentiins," Nat. Rev. Mol. Cell. Biol. 1:217-224 (2000).			
	BZ WESTERMAN et al., "The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease," J. Neurosci. 22:1858-1867 (2002).				
	CA	WILSON et al., "The use of mRNA display to select high-affinity protein-binding peptides," PNAS 98:3750-3755 (2001).			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/

Examiner Signature /Stephen Gucker/	Date Considered	03/31/2008
-------------------------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of the form with next communication to applicant.

Applicant's unique citation esignation number optional, "Applicant is to place a check mark here if English language Translation is attached.